Individuals practice these MSNCB boot camp to get 100 percent marks

killexams.com offers 100 percent free PDF Questions for attempts before purchase. We are certain that you will fulfill the nature of MSNCB boot camp with actual test questions that we give. Simply register for complete MSNCB Medical-Surgical Nursing Certification questions bank and download your duplicate. Download VCE tests test system for training and you will feel certain before you face a genuine MSNCB test.

Exam Code: MSNCB Practice exam 2022 by Killexams.com team
MSNCB MSNCB Medical-Surgical Nursing Certification

Our affiliated professional association, the Academy of Medical-Surgical Nurses, offers the Medical-Surgical Nursing Certification Review Course. It is a 2-day course designed for nurses preparing to take the Certified Medical-Surgical Registered Nurse (CMSRN®) Certification Exam.

In order to meet the varied needs of nurses and facilities, AMSN offers the course in a number of live and independent study formats, including bringing it to your facility or accessing it through the AMSN Online Library.

An alternative to nurses preparing for the CMSRN exam is the Focused CE Series, a collaboration between AMSN and nurse.com. The Focused CE Series is a blended learning model that combines weekly online CE course readings, weekly live webinar presentations, and an online forum for information exchange and networking with peers.

1. Helping Role
- Maintain an environment in which patient confidentiality is assured.
- Assess patient's level of comfort/pain.
- Act as an advocate to help patient meet needs/goals.
- Acknowledge, respect, and support emotional state of patient and/or family as they experience and/or express their emotions.
- Assist patients to achieve optimal level of comfort, using an interdisciplinary approach.
- Modify plan of care to achieve patient's optimal level of comfort, i.e., pharmacological interventions, heat, cold, massage, positioning, touch, etc.
- Provide a therapeutic environment, considering privacy, noise, light, visitors'/providers' interaction with patients.
- Provide culturally competent patient care, including education.
- Support family involvement in accordance with patient's wishes regarding caregiving and decision making.
- Assess for potential for self-harm.
- Identify need of patient/family for support systems/resources and make appropriate referrals.
- Work on behalf of patient/family to help resolve ethical and clinical concerns.
- Coordinate care across multiple settings.
- Identify, acknowledge, support, and facilitate patient/family decisions regarding end-of-life care.
- Identify signs of domestic or intimate partner violence.
- Assess and provide for spiritual needs of patients and families.
- Identify ethical issues in clinical practice and facilitate a resolution with patient, family, and staff.

2. Teaching/Coaching Function
- Assess the patient's and family's readiness and ability to learn.
- Identify barriers to learning.
- Prepare/educate patient for transition in care, e.g., discharge to home or other facility.
- Provide information and rationales related to diagnosis, procedures, self-care, prognosis, wellness, and modifiable risk factors.
- Utilize opportunities for spontaneous education.
- Encourage patient's and family's participation in establishing educational goals.
- Develop and implement an individualized teaching plan for patient and/or family.
- Evaluate and modify teaching plan based on achievement of pre-established and ongoing learning needs.
- Assist staff in identifying educational needs of patients and their families.
- Assist staff in selecting/developing educational materials appropriate for intended learner(s).
- Teach patient and family about available community resources.

3. Diagnostic and Patient Monitoring
- Conduct and document a comprehensive baseline assessment.
- Anticipate patient's response to treatment and monitor for potential problems.
- Reassess patient based on established standards of care at appropriate intervals.
- Interpret results of laboratory and diagnostic studies and take appropriate action.
- Use invasive and non-invasive methods to collect data.
- Analyze all patient data in formulating a plan of care.
- Participate in medication reconciliation at transitions of care.
- Anticipate the patient's response and needs related to physiological, psychosocial sexual, spiritual, and cultural aspects of his/her illness.
- Prioritize identified problems and modify the plan of care to achieve the best possible outcomes.
- Develop an individualized plan of care congruent with patient goals.
- Identify purpose and appropriateness of diagnostic studies.

4. Administering and Monitoring Nursing Interventions
- Administer medications accurately and safely.
- Identify subtle changes in patient's assessment to prevent deterioration of patient status.
- Assess patient's level of consciousness.
- Monitor patients for therapeutic responses, reactions, untoward effects, toxicity, and incompatibilities of administered medications.
- Implement measures to ensure adequate oxygenation and gas exchange.
- Monitor and implement measures to prevent alterations in skin integrity.
- Initiate, maintain, and monitor intravenous therapy.
- Identify, document, and report deviations from expected findings.
- Monitor for signs and symptoms of complications of disease processes.
- Implement measures to address threats to patient safety, e.g., falls, seizures.
- Maintain patent airway.
- Maintain integrity and prevent infection of invasive drainage systems, e.g., catheters, percutaneous drains.
- Implement measures to maintain adequate hydration and electrolyte balance.
- Provide care to patients on continuous cardiac monitoring.
- Use adaptive/assistive devices for mobility, immobility, positioning, and comfort.
- Interpret cardiac rhythm strips.
- Monitor for complications of musculoskeletal trauma and surgical procedures.
- Perform a neurovascular assessment, e.g., extremities, flaps, grafts.
- Provide optimum nutrition during hospitalization, allowing for cultural and individual preferences.
- Identify and implement transmission-based precautions based on patient's history and symptoms.
- Monitor effectiveness of nutritional interventions.
- Develop and implement a wound management strategy.
- Care for patient receiving IV patient-controlled analgesia
- Perform central line dressing change.
- Administer heparin drip
- Apply and/or monitor devices used to immobilize affected area, e.g., cast, splint, collar, etc.
- Care for patient receiving epidural analgesia
- Provide care for patients who have chest drainage systems.

5. Effective Management of Rapidly Changing Situations
- Recognize signs that a patients condition is deteriorating and take appropriate action.
- Obtain appropriate orders to address a change in the patients condition,
- Determine priorities in rapidly changing situations.
- Use existing guidelines/protocols/policies to respond to changing patient situations, e.g., hypoglycemia, wound dehiscence.
- Use existing guidelines/protocols/policies to respond to urgent and emergent situations, e.g., acute chest pain, stroke.
- Initiate basic life support.

6. Monitoring/Ensuring Quality Health Care Practices
- Communicate effectively to the healthcare team.
- Question/clarify orders as appropriate.
- Incorporate evidence-based practice into the patient's plan of care.
- Coordinate and/or participate in interdisciplinary activities to ensure consistent patient outcomes, e.g., core measures.
- Report system failures, e.g., chain of command, equipment, safety, medication administration, computer systems.
- Assist nursing staff in incorporating evidence-based practice and quality improvement into practice.
- Participate in quality improvement activities.
- Identify clinical problems for further investigation.

7. Organizational and Work-Role Competencies
- Practice in accordance with the rules and regulations of the state board of nursing in state(s) of licensure.
- Adhere to the Scope and Standards of Medical-Surgical Nursing Practice.
- Utilize electronic/computer resources to optimize patient care.
- Set priorities based on assignment, unit, and institutional needs.
- Act as a professional role model.
- Participate as an active member of the interdisciplinary healthcare team.
- Delegate patient care assignments based on competency levels and scope of practice of healthcare team members.
- Act as a resource for other nurses on the unit.
- Provide collaborative, interdisciplinary, coordinated care.
- Incorporate strategies that support effective team dynamics in a caring and nurturing environment.
- Evaluate own practice based on established standards of care.
- Evaluate nursing care based on outcome criteria.
- Recognize unsafe work practices (nurse/patient ratio, ergonomics, standard precautions, etc.) and intervene appropriately.
- Identify, develop, and implement strategies to reduce readmissions.
- Use the chain of command appropriately.
- Serve as consultant to nursing staff and other disciplines.
- Coordinate and/or participate in interdisciplinary activities to ensure consistent patient outcomes, e.g., core measures.
- Identify, develop, and implement strategies to decrease length of stay while improving patient/family/staff satisfaction and patient care.
- Provide expert support to unit educators, preceptors, and nurse managers.
- Follow institutional policies and procedures in response to an internal or external crisis or event.
- Serve as preceptor/mentor for students and staff.
- Assist with data collection (e.g., patient outcomes, nurse-sensitive indicators).

MSNCB Medical-Surgical Nursing Certification
Medical Medical-Surgical availability
Killexams : Medical Medical-Surgical availability - BingNews https://killexams.com/pass4sure/exam-detail/MSNCB Search results Killexams : Medical Medical-Surgical availability - BingNews https://killexams.com/pass4sure/exam-detail/MSNCB https://killexams.com/exam_list/Medical Killexams : Ambulatory Surgical Centers & Hospitals Account for Highest Usage of Medical Connectors: Fact.MR Analysis

Rockville, Dec. 08, 2022 (GLOBE NEWSWIRE) -- As per this new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global medical connectors market is valued at US$ 2.74 billion in 2023 and is predicted to expand at a CAGR of 6% from 2023 to 2033.

Medical connectors help in connecting other medical devices (such as tubes, catheters, syringes, and more). Based on their function, various types of connectors are available in the market such as medical gas connectors, medical hose connectors, medical tubing connectors, medical air connectors, medical electrical connectors, and more Medical electric connectors are components or tools used to connect or detach circuits electrically, among other items. They can be connected and disconnected manually or with basic tools, without the need for specialized equipment or procedures such as soldering.

Medical equipment and laboratory equipment are connected using cable assemblies. They typically have an abrasion-resistant jacket that offers relatively low surface friction & mechanical durability while transmitting power and/or data.

Hospitals & clinics and ambulatory surgical centers make high use of medical connectors due to the high footfall of patients. Flat silicone surgical cables are widely preferred due to their better chemical resistance quality.

Download a Free demo Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=8020

North America and Europe are leading marketplaces for medical connectors due to the presence of top manufacturers and advanced healthcare infrastructure. Asia Pacific is growing as a profitable market for medical connector manufacturers due to the developing healthcare industry across the region.

Key Takeaways from Market Study

  • The global market for medical connectors is projected to reach US$ 4.91 billion by 2033.
  • Japan's market is predicted to expand at a CAGR of 6% during the forecast period.
  • Demand for medical connectors in China is expected to rise at an impressive CAGR of 5.5% during the forecast period.
  • Demand for medical connectors from ambulatory surgical centers is predicted to increase at a high CAGR of 6% from 2023 to 2033.

"Rising prevalence of chronic diseases, rapidly growing medical sector across the world, and increasing rate of senior population are driving the usage of medical connectors," says a Fact.MR analyst.

Key Segments Covered in Medical Connectors Industry Research

  • By Product:
    • Push-pull Connectors
    • Hybrid Circular Connectors & Receptacle Systems
    • Radio-frequency Connectors
    • Flat Surgical Silicone Cables
    • Embedded Electronics Connectors
    • Disposable Plastic Connectors
    • Power Cords with Retention Systems
    • Lighted Hospital-grade Cords
    • Magnetic Medical Connectors
  • By Application:
    • Patient Monitoring Devices
    • Therapeutic Devices
    • Diagnostic Imaging Devices
    • Cardiology Devices
    • Analyzers & Processing Equipment
    • Respiratory Devices
    • Dental Instruments
    • Endoscopy Devices
    • Neurology Devices
    • Enteral Devices
  • By End User:
    • Hospitals & Clinics
    • Ambulatory Surgical Centers
    • Diagnostic Laboratories & Imaging Centers
  • By Region:
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

Get Customization on this Report for Specific Research Solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=8020

Winning Strategy

To increase their market share, meet end users' needs, and earn more profits, top players are focusing on developing technologically sophisticated medical connectors and collaborations with others.

  • TE Connectivity leading producer of connectors and sensors purchased 3 companies in September 2021, which are experts in usability testing, clinical research, production and the development of microfluidic cartridges and blister reagent packages.

Key Companies Profiled

  • Amphenol Corporation
  • Aptiv PLC
  • Esterline Technologies Corporation
  • Fischer Connectors SA
  • ITT Corporation
  • Lemo SA
  • Molex LLC
  • Samtec, Inc.
  • TE Connectivity Ltd.
  • Smiths Interconnect

Explore Our Safe & Secure Payment Options for Quick Buy https://www.factmr.com/checkout/8020

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global medical connectors market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.

The study divulges essential insights on the market on the basis of product (push-pull connectors, hybrid circular connectors & receptacle systems, radio-frequency connectors, flat surgical silicone cables, embedded electronics connectors, disposable plastic connectors, power cords with retention systems, lighted hospital-grade cords, magnetic medical connectors), application (patient monitoring devices, therapeutic devices, diagnostic imaging devices, cardiology devices, analyzers & processing equipment, respiratory devices, dental instruments, endoscopy devices, neurology devices, enteral devices), and end user (hospitals & clinics, ambulatory surgical centers, diagnostic laboratories & imaging centers), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Check out more related studies published by Fact.MR Research: 

Disposable Hot Cups & Lids Market - Disposable hot cups & lids are a highly economical solution for serving customers at a food or beverage outlet, or serving a large number of guests in a gathering. Consumer preference is shifting towards disposable hot cups & lids due to the integrity of a single use foodservice product.

Lyophilization Market - In 2021, the global lyophilization market was valued at US$ 926.1 million and is anticipated to reach US$ 2.3 billion by 2032, expanding at a high 8.8% CAGR over the 2022-2032 period.

Disposable Medicine Measuring Cups Market - The global disposable medicine measuring cups market is anticipated to expand at a CAGR of ~6.4%, during the forecast period.

Electroceuticals / Bioelectric Medicine Market - The global electroceuticals / bioelectric medicine market is valued at US$ 24.5 billion and is projected to attain a revenue of US$ 32.1 billion by the end of 2026. This Fact.MR survey predicts worldwide demand for electroceuticals / bioelectric medicines to increase rapidly at a CAGR of 6.9% over the next four years.

3D Printing Medical Devices Market - The global 3D printing medical devices market is estimated at USD 2.9 Billion in 2022 and is forecast to surpass USD 11.5 Billion by 2032, growing at a CAGR of 14.5% from 2022 to 2032.

About Us:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Tel: +1 (628) 251-1583


© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Thu, 08 Dec 2022 04:00:00 -0600 text/html https://www.benzinga.com/pressreleases/22/12/g30012637/ambulatory-surgical-centers-hospitals-account-for-highest-usage-of-medical-connectors-fact-mr-anal
Killexams : Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.

NEW BRUNSWICK, N.J., Dec. 7, 2022 /PRNewswire/ -- Pipeline Medical, a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medical professionals around the country, recently announced the addition of Jeuveau® (prabotulinumtoxinA-xvfs) by Evolus, Inc. (NASDAQ: EOLS).

Pipeline Medical

Launched in 2019, Jeuveau® is a botulinum toxin type A, a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to Boost the look of moderate to severe frown lines between the eyebrows (glabellar lines).

"Pipeline Medical was founded by aesthetic practitioners; as such, we are always looking to provide our customers with the best products in the market. Today we are thrilled to offer Jeuveau® to our customers. Jeuveau® is a top-performing toxin, dedicated strictly to aesthetics, available at an unbeatable price point," says  Zachary Ducharme, CEO, of Pipeline Medical.

As a MedTech marketplace, Pipeline Medical aggregates medical supplies and pharmaceuticals from multiple manufacturers, suppliers, and distributors. Providing customers with a one-stop-shop and streamlined purchasing experience. Pipeline's consistency in product availability at low prices has led Pipeline Medical to tremendous growth in the past decade.

Pipeline Medical caters to many highly influential plastic surgeons, medical spas, dermatologists, and aesthetic practices around the country.

"At Evolus, our goal is to help providers reach the next generation of consumers with a precise product and a unique business model," said Kurt Knab, SVP of Sales  at Evolus. "We look forward to partnering with Pipeline Medical to increase access to Jeuveau and expand adoption among a large and impactful group of providers."  Along with the product benefits, Pipeline Medical looks forward to offering its customers Evolus' co-branded marketing model. The co-branded marketing model offers customers a wide range of advertising options, including digital ads, billboards, and most recently, streaming television advertisements, with a direct call to action to book appointments using a smartphone and QR code. 

Jeuveau® is the highest-selling aesthetic product launched since 2019, with sales to more than 8,800 practices nationwide and a reorder rate of over 70 percent. These practices have administered more than 2 million treatments of Jeuveau® to date.

Pipeline Medical has gained the trust of plastic surgeons and physicians for its mastery of supply chain management and ability to offer 20-40% discounts on medical supplies. Even during the height of the pandemic, the company shipped essential products and medical supplies around the country with excellent efficiency.

Pipeline Medical offers a wide range of products, including surgical instruments, sutures, medical supplies, surgical supplies, and pharmaceuticals. The company is constantly innovating and introducing new products that make the lives of medical providers easier.

About Pipeline Medical

Pipeline Medical is a single-source medical supply provider serving non-acute customers by acting as a GPO, distributor, and material manager, providing medical practitioners with significant savings of time and money.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Its mission is to become a global, multi-product aesthetics company based on its flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology.

Contact:
Zachary Ducharme
CEO of Pipeline Medical
zducharme@pipelinemedical.com
+1 (646) 887-7059

Pipeline Medical and Evolus collaboration

Cision View original content to obtain multimedia:https://www.prnewswire.com/news-releases/leading-medtech-marketplace-pipeline-medical-now-provides-jeuveau-by-evolus-inc-301692550.html

SOURCE PIPELINE MEDICAL

Wed, 07 Dec 2022 01:14:00 -0600 en text/html https://markets.businessinsider.com/news/stocks/leading-medtech-marketplace-pipeline-medical-now-provides-jeuveau-by-evolus-inc-1031958173
Killexams : Addressing Women’s Needs in Surgical Instrument Design

PRODUCT DEVELOPMENT INSIGHT

Wiklund

Rudnick

Liberatore

Popular television shows portray the changing demographics of people in medicine. In weekly episodes, gender-balanced ensembles of attractive women and men portray doctors, each taking their turn at cardiopulmonary resuscitation (Clear!...Thump!). Although the scenes are make believe, they reflect a genuine trend in the United States and abroad.

Indeed, the American Medical Association's latest figures indicate that 26.6% of all U.S. doctors are women, up dramatically from 7.6% in 1970.1 Obstetric, gynecologic, and pediatric specialties are reportedly drawing the most women, with 74.5%, 69.1%, and 51.9%, respectively, of all new residents in 2004 being women.2 Even more telling, about 50% of all U.S. medical school applicants are now women.3 This suggests that the total proportion of practicing female doctors will grow dramatically in the coming years, eventually achieving parity with male doctors.

The demographic shift has significant implications for surgical instrument designers. Surgical instruments have traditionally been designed for men. Therefore, the demographic shift calls for designers to broaden their product requirements. They must address the needs of women in addition to men. According to many women surgeons who have struggled with instruments designed almost exclusively for men, the changes are overdue and there are continuing consequences. Viviane Connor, MD, codirector of the section of minimally invasive gynecology at Cleveland Clinic (Weston, FL), observes, “I've never seen a surgical instrument that was too small for my hand. The average new instrument is still too large and bulky for the average female surgeon. Many require the application of excessive force. Some stretch a woman's hand to the limit, or even require the use of two hands.”

Size and Strength Comparisons

To date, women have had to cope with instruments designed for hands that are, in most cases, larger and stronger than theirs. As shown in Figure 1, the 5th-percentile woman's hand is considerably smaller than the 95th-percentile man's hand in every dimension. The differences are even more pronounced at the 1st and 99th percentiles, where thumb widths, for example, range from a mere 0.6 to 1.2 in.—twice as wide (see Table I).

Strength differences are also dramatic.4 The 2.5th-percentile woman's squeezing grip strength, for example, is 53 lbf, while the 97.5th-percentile man can exert 147 lbf. For the same individuals, fingertip pinch strengths range from 7.5 to 30 lbf. As a rule, designers can figure that the average woman's hands, and upper extremities in general, are about half as strong as the average man's, but the difference is exaggerated at the extremes, as illustrated by the earlier data.

Unfortunately, data for individuals at the extremes are spotty, especially for women. Therefore, designers interested in estimating extreme values can use the formulas presented in Table II. However, for those formulas to work, designers must be able to obtain mean (M) and standard deviation (SD) values for a given measurement.

Consequences of Poor Ergonomics

Keeping the biomechanical differences between men and women in mind, myriad usability problems can arise from women using oversized tools. As Connor described, women with average to small-sized hands need to stretch them to grip widely spread handles. Small-diameter fingers will float in finger holes, potentially causing instability and physical discomfort. Instruments requiring an especially firm squeeze might place repetitive stresses on weaker hands. For example, a tool contoured for a comparatively large hand could contact a small hand in the wrong spot, also causing unsteadiness and possibly pain.

A recent survey sponsored by Ethicon collected hand size and strength data from the participating surgeons. The data suggest that almost 50% of all surgical instruments feel too large to grip comfortably and feel improperly contoured to the hand. Moreover, respondents with particularly small hands opined that 80–90% of all surgical instruments are not ergonomically suitable for their particular use. In addition, many tools require the surgeons to apply forces that are difficult for them to deliver. Although the data demo from the survey is not statistically significant given the small number of measurements, it does illustrate the range of female hand size and strength for a specialized user population that is underrepresented in available databases.

Susan Johnson, MD, a gynecologist practicing at Legacy Portland Hospitals (Portland, OR), agrees that women make adjustments to ill-fitting instruments. “Most surgical devices are designed with men in mind, which places women at a disadvantage,” she says. She worries that women with particularly small hands might turn away from a career in surgery because the tools of the trade are generally designed for larger hands.

Working with oversized tools can make any task more difficult. This is certainly not to say that women surgeons are less effective when forced to use oversized surgical instruments— humans are generally good at adjusting to design shortcomings. Still, logic suggests that task performance peaks when tools are properly sized to the user's body. Moreover, device design should adapt to people, not the other way around.

User-Centered Design

Designing devices to adapt to people is what user-centered design is all about. The philosophy holds that a design should be based on user needs rather than the demands of a particular technology or designer's preferences. Many successful products in many different industries have arisen from clearly defined user requirements. For example, the Oxo can opener is notable for its soft-feeling handle and smooth, almost effortless operation. Originally it was geared toward use by individuals with arthritic hands. In other words, it was designed for hands possessing limited strength and range of motion. However, the product satisfied not only the needs of customers with hand impairments, but also people with normal use of their hands. Therefore, the product had universal appeal and stands as an exemplar of universal design.

Concepts like the one described here can be borrowed and expanded upon when designing surgical instruments. A user-centered design process should lead directly to designs that accommodate both men and women. The designs should require little, if any, physical adjustment. In cases where one tool simply cannot accommodate both large- and small-handed individuals, it would be appropriate to produce two or more models. Of course, working with accurate human factors data regarding men and women's needs is essential.

Data Sources

The data comparisons presented earlier in this article represent the tip of the iceberg. This kind of data—called anthropometrics—is available in many publications and software applications.

One of the more popular, albeit simplified, sources of data is called Humanscale. It is a set of nine plastic charts and associated booklets (see Figure 2). Simply set one of the charts' rotating plastic dials on “small woman” and it provides various body size and strength values for the 5th-percentile female. Although academics may seek a more extensively referenced data source, Humanscale is nonetheless a useful tool. It provides a good starting place for designers interested in creating products that fit intended users' physical characteristics.

A more basic, practical, and reasonably effective approach is to enlist the support of people who represent the physical extremes. For example, within a company that employs dozens or hundreds of people, it would probably be easy to find individuals with very small hands and others with extremely large ones. Although they might be perfectly pleased with their own hands, designers may think of them as worst cases. Designers can use them as reference points for judging the fit and usability of instruments at the extremes.5

Going in the other direction in terms of rigor and complexity, designers might also use advanced software tools to support their product development efforts. Notable software applications include ManneQuinPro, JACK, and the Santos Hand. The latter can simulate the movement of a hand based on a computer model incorporating 25 degrees of freedom (meaning that it can be moved in 25 different ways, e.g., up, down, left, right, etc.).

Conducting special studies is another way to gather pertinent anthropometric data. For example, as part of the aforementioned survey of female surgeons, researchers recorded data during various dimensional and strength measurements. Key data (measured and calculated) for this subpopulation are presented in Table III. However, it should be noted that the demo size was quite small.

The female surgeons were asked to pinch a force gauge with what they considered to be a comfortable amount of pressure for a short period (5 seconds). The results showed that the surgeons used about two-thirds of their maximum pinching force. However, when the surgeons were asked to grip a force gauge with a comfortable amount of pressure for a short period (4 seconds), they used a bit less than half of their maximum gripping force. These comfortable force levels would undoubtedly decline as the force application duration increases.

Applying the Data

If designing for the average user causes misfit designs, disregarding the needs of women altogether is even worse. A surgical instrument designed specifically for the average man's hand probably would not meet the needs of large- or small-handed individuals, male or female. But many more women, perhaps even a large majority, would have to cope with physical incompatibilities.

The best approach is actually to design in a gender-neutral manner. Designers should try to accommodate hands ranging widely in size and strength, rather than men versus women. After all, some men have small hands too—5 out of 100 men have shorter hands than 3 out of 4 women (7.2 versus 7.3 in.).6 Depending on the surgical instrument, one solution might cover the full range of users. Alternatively, there may be a need for two, three, four, or even more models of the same basic instrument to accommodate all users. For example, there are at least eight different sizes of surgical gloves (sizes 5.5 to 9).

The consequence of designing explicitly for an average-sized individual—male or female—is that the resulting product may accommodate very few users.

Figure 3. A hemostatic forcep. Small differences in finger-hole size could affect ease of use.

Consider the nonmedical example of jewelry. A size 8 ring may fit only an average person and be too loose or too tight for people with slightly narrower or thicker fingers. Therefore, U.S. adult ring sizes commonly range from 4 (113¼16 in.) to 13 (215¼16 in.). Accordingly, the key is to create medical device designs that work for the widest possible range of individual characteristics without compromising performance. Obviously, a ring needs to fit snugly but not too tightly, so rings need to be made in many sizes. But consider the finger holes in a hemostatic forcep (see Figure 3). A small difference in finger circumference could have a significant effect on the fit. Notably, the index finger circumferences (measured at the proximal interphalangeal joint) of the female surgeons surveyed averaged 2.35 in., but varied over a range of 0.44 in.

Conclusion

Gender-biased products are prevalent in society. Some products are definitely geared toward either men or women. Particularly large or small individuals can confirm there is also a bias toward average-sized people. This explains why tall men bang their heads on aircraft ceilings and small women cannot reach the overhead luggage compartments. The common solution to such problems is to duck down or ask for help. However, user adjustments to improperly sized medical products can make for less-than-optimal performance and customer dissatisfaction. Moreover, nobody wants his or her surgeon struggling to grasp an ill-fitting instrument. Establishing appropriate anthropometric requirements at the start of new product development efforts can help solve this problem. Given proper data and follow-up user testing with representative users, the chance of producing ill-fitting surgical tools will be greatly reduced. Manufacturers should remember that half of the new doctors in the United States will be women in the not-too-distant future. In response, they must design products that will accommodate both ends of the user hand-size spectrum.

Michael Wiklund is president of Wiklund Research & Design Inc. (Concord, MA). Jim Rudnick works in research and development at Stryker (Kalamazoo, MI), and Jessica Liberatore is an industrial designer with Ethicon (Somerville, NJ).

REFERENCES

1. “Table 1—Physicians By Gender,” in Physician Characteristics and Distribution in the U.S., 2006 Ed. [online] (Chicago: American Medical Association, 2006); available from Internet: www.ama-assn.org/ama/pub/category/12912.html.
2. “Appendix II. Graduate Medical Education,” Journal of the American Medical Association 297, no. 9 [online] (2005): 1129–1131; available from Internet: www.ama-assn.org/ama/pub/category/12915.html.
3. “Table 2—Women Medical School Applicants,” in Women in U.S. Academic Medicine Statistics and Medical School Benchmarking 2004–2005 [online] (Washington, DC: Association of American Medical Colleges, 2006); available from Internet: www.ama-assn.org/ama/pub/ category/12913.html.
4. “Humanscale 4a—Human Strength” (Cambridge, MA: MIT Press, 1981).
5. Michael Wiklund, “Defining and Designing for Worst-Case Users,” Medical Device & Diagnostic Industry 28, no. 7 (2006): 52–59; available from Internet: www.devicelink.com/mddi/archive/06/07/ 012.html.
6. “Humanscale 6b—Hand Length” (Cambridge, MA: MIT Press, 1981).

Copyright ©2006 Medical Device & Diagnostic Industry

Mon, 28 Nov 2022 10:00:00 -0600 en text/html https://www.mddionline.com/news/addressing-womens-needs-surgical-instrument-design
Killexams : Tomlin Medical offers surgical instruments in Australia No result found, try new keyword!A medical equipment company in Australia named Tomlin Medical offers a wide selection of medical and surgical equipment at affordable costs. General practitioners and specialty clinics can purchase ... Tue, 06 Dec 2022 09:37:00 -0600 https://markets.buffalonews.com/buffnews/article/getnews-2022-12-6-tomlin-medical-offers-surgical-instruments-in-australia Killexams : Medical management of early pregnancy loss cost-effective compared with office uterine aspiration

Early pregnancy loss (EPL), or miscarriage, is common. With an increased availability of highly sensitive pregnancy tests and early ultrasounds, many patients are diagnosed with an EPL before the onset of symptoms. Once diagnosed, pregnant individuals have 3 treatment routes available to them: expectant management (watching and waiting), surgical intervention (uterine aspiration in the office or operating room), or medical management (using medications to induce uterine contractions and expel tissue). These 3 options differ in effectiveness, patient experience, and cost.

With improved medication management effectiveness, patient and clinician interests in expanding access to medication management have increased and the COVID-19 pandemic has highlighted the importance of treatment options that minimize in-person clinic visits.

The comparative cost-effectiveness of medication management and in-office management has significant implications for clinical care and reproductive health policy. If medication management is preferred by many patients, decreases the need to access in-person clinical care during a pandemic, and is found to be cost-effective, clinicians and policy makers should increase efforts to Boost mifepristone availability and reduce access burdens.

Given the clinical efficacy of medical management of EPL using mifepristone pretreatment, and its proven cost-effectiveness compared with misoprostol-alone treatment for EPL, authors Nagendra D, Gutman SM, Koelper NC, et al developed a decision analytical model combining the Pregnancy Failure Regimens (PreFaiR) trial data and data from the published literature to assess the cost-effectiveness of medical management with mifepristone pretreatment followed by misoprostol ("medical management") compared with an office based uterine aspiration arm ("uterine aspiration") for the treatment of EPL.

The analysis was from the healthcare sector perspective with a 30-day time horizon. Costs were in 2018 US dollars. Effectiveness was measured in quality-adjust life-years gained and the rate of complete gestational sac expulsion with no additional interventions. The primary outcome was the incremental cost per quality-adjust life-year gained. Sensitivity analysis was performed to identify the key uncertainties.

Mean per-person costs were higher for uterine aspiration than for medical management ($828 vs $661; P<.004).

Uterine aspiration more frequently led to complete gestational sac expulsion than medical management (97.3% vs 83.8%; P<.0001); however, estimated quality-adjust life-years were higher for medical management than for uterine aspiration (0.082 vs 0.079; P<.0001). Medical management dominated uterine aspiration, with lower costs and higher confidence interval. The probability that medical management is cost-effective relative to uterine aspiration is 97.5% for all willingness-to-pay values of $5600/quality-adjust life-year. Sensitivity analysis did not identify any thresholds that would substantially change ><.0001).

Medical management dominated uterine aspiration, with lower costs and higher confidence interval. The probability that medical management is cost-effective relative to uterine aspiration is 97.5% for all willingness-to-pay values of $5600/quality-adjust life-year.

Sensitivity analysis did not identify any thresholds that would substantially change outcomes.

This study demonstrated that from the healthcare perspective, medical management with mifepristone pretreatment followed by misoprostol was cost-effective compared with office uterine aspiration for EPL treatment, with higher effectiveness (QALYs) and lower costs.

Medical management of EPL with mifepristone pretreatment and misoprostol has been found to be costeffective compared with office uterine aspiration, with similar QALYs and lower costs, making it a high-value care alternative. Increasing access to mifepristone and eliminating unnecessary restrictions will Boost early pregnancy care.

Source: Nagendra D, Gutman SM, Koelper NC, et al. Medical management of early pregnancy loss is cost-effective compared to office uterine aspiration. Am J Obstet Gynecol 2022;227:737.e1-11. https://doi.org/10.1016/j.ajog.2022.06.054

Tue, 06 Dec 2022 14:30:00 -0600 en text/html https://medicaldialogues.in/obstetrics-gynaecology/news/medical-management-of-early-pregnancy-loss-cost-effective-compared-with-office-uterine-aspiration-103304
Killexams : CRO Medical Set To Introduce New Medical Technology for Prehospital Treatment

Missoula, Montana--(Newsfile Corp. - November 30, 2022) - CRO Medical, a commercial-stage medical device company committed to bringing hospital-equivalent care to the field and improving trauma care in the military and civilian medical markets, has announced the future rollout of its new prehospital suction device slated for the middle of 2023.

CRO Suction Unit

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8668/146076_be85111f04faa9dd_001full.jpg

The innovative CRO Suction Unit will allow medics to perform various medical procedures requiring suction near the point of injury. Due to existing limitations with other devices in this category, medics often have to utilize unreliable improvised solutions, leading to substandard levels of care. The extremely lightweight and highly portable device will be the smallest version available on the market, making it ideal for first-line aid bags.

"Traditionally, medical innovations in trauma have come from the military and are later adopted by the civilian market," says Jeff Boardman, Founder, and CEO of CRO Medical. "We feel the best entry into the market is to design products that capture future military medical requirements that will later be adopted by a broader audience. Our competitive advantage in the prehospital space is serving elite special operations medics and delivering those technology innovations to optimize the care of critically injured patients in the field. There are plenty of innovations needed in the prehospital market. Currently, the military is leading the effort to adapt medical equipment innovations to best practices in medical protocols."

The drawback of traditional suction units is primarily due to their size and weight. Even portable options have less desirable proprietary features, such as custom battery packs, which are heavy and are not optimal for field use. CRO Medical's technology utilizes standard CR123 batteries, which can be replaced quickly, providing an indefinite run time for the device with appropriate resupply.

"The device's size has been drastically reduced," says Boardman. "We achieved this by containing suction pressure in small internal chambers using a series of highly responsive valves. The waste collection system is a disposable 500ml collection bag. When the waste collection bag fills, replace it to continue using the device."

The military was the first to show interest in CRO Medical's technology. According to Boardman, units specializing in immediate surgical intervention for wounded soldiers require smaller and lighter solutions to perform Damage Control Surgery. Suction is considered the standard of care for various common field procedures, including airway procedures, chest injury management, and damage control surgery.

"Our technology has far-reaching implications on how suction is delivered to severely injured patients across the continuum of care," says Boardman. "We are working to make this equipment available to all first responders, not just the military. The rollout of this device will mean a higher standard of care delivered to patients in the field, where survivability often depends on the speed in delivering definitive treatments."

The CRO Suction Unit is currently in final regulatory status with the FDA and will launch to military units by mid-year 2023. The product will be available directly to the company or through various DLA Prime Vendor Contracts such as ECAT, DAPA, GSA, and FedMall.

CRO Medical has multiple medical equipment contracts with the United States military. The Defense Logistics Agency spends over $2B in medical materials procurement annually. While the company is primarily a defense contractor, due to the variety of medical roles requiring lightweight solutions, CRO technology aims to serve a much larger civilian prehospital market, including ambulance, fire, and search and rescue customers.

Boardman reveals the company plans to expand its medical technology portfolio to compete in civilian prehospital medicine and government contracting.

About CRO Medical

CRO Medical Founder and CEO Jeff Boardman is a former U.S. Navy Special Amphibious Reconnaissance Corpsman and graduate of the Naval Special Operations Medical Institute at Ft. Bragg. He established CRO Medical to enhance critical care resuscitation in remote and austere environments. In 2017, after leaving the military, he founded CRO, LLC, a medical technology transfer firm. One of his goals was to bring more capable tools to the field to enhance medical treatment in remote areas.

For more information about CRO Medical and its new CRO Suction Unit device, please visit www.cromedical.com or contact:

Jeff Boardman
jboardman@cromedical.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146076

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Wed, 30 Nov 2022 00:04:00 -0600 text/html https://www.benzinga.com/pressreleases/22/11/29907016/cro-medical-set-to-introduce-new-medical-technology-for-prehospital-treatment
Killexams : Medical Metaverse Company, apoQlar, Receives FDA 510(k) Clearance for its Mixed Reality Surgical Planning Platform, VSI HoloMedicine®

HAMBURG, Germany, Dec. 5, 2022 /PRNewswire/ -- apoQlar, a German medical technology company, today announced it has received FDA 510(k) Class II clearance for VSI HoloMedicine®, a pioneering mixed reality software device enabling surgeons to plan complex procedures using the power of immersive 3D holographic technology. With this clearance, the USA becomes the 30th country for apoQlar to receive medical certification in. apoQlar will extend its distribution of VSI HoloMedicine® in the USA for clinical use through its subsidiary in Miami, Florida, with availability expected in the second quarter of 2023.

A Chief of Visceral Surgery visualizes 3D holograms in medical mixed reality (PRNewsfoto/apoQlar GmbH)

Following this major achievement, apoQlar is now raising a Series A round, its first ever fundraising campaign, to scale VSI Holomedicine® as the foundation of modern surgical care.

"With mixed reality, we are no longer bound to physical objects in a physical world. We can leverage digital objects and services on top of the real world for equal or greater utility and usually at a fraction of the cost. Mixed Reality is a completely new way for people, and in our case surgeons, physicians and technologists, to continue to experience the real world around them but with an entire virtual layer placed on top" says Sirko Pelzl, Co-Founder & CEO of apoQlar.

VSI HoloMedicine® gives surgeons an almost "x-ray vision" perspective in surgical planning processes using 3D holographic technology. Physicians across any medical field can now plan surgeries in 3D and visualize medical data inside or outside of the operating room. Using Microsoft's HoloLens 2, a mixed reality head-mounted display (HMD), surgeons can transform otherwise flat CT, Angio CT, MRI, CBCT, PET, and SPECT sources into interactive 3D holograms. Sirko continues to say that "we are excited to finally offer VSI HoloMedicine® to Boost surgical outcomes for patients and to provide surgeons with sophisticated surgical planning tools to enhance their overall planning process."

"FDA clearance marks a major milestone for us. We are a young company, but this serves as a true testament of our collective team mindset and diligence" says Liliana Duarte, COO of apoQlar. This is the latest achievement for apoQlar in their global expansion plan and serves as a tailwind for further market expansion efforts into South-East Asia, India, and the Gulf Coast States for 2023.

Please visit www.apoQlar.com or www.linkedin.com/company/apoQlar/ to learn more.

About apoQlar

apoQlar was founded in 2017 in Hamburg, Germany to provide healthcare a new perspective. apoQlar developed an affordable medical metaverse technology, VSI HoloMedicine®, that brings the crucial third dimension to surgical planning, remote consultation, patient education and medical training. VSI HoloMedicine® holds FDA 510(k), CE Class I and HSA Class A medical certifications for clinical use in 30 countries. The full intended use description of VSI HoloMedicine can be found here.

If you would like more information about VSI HoloMedicine® for your clinical & education institution or interested in learning more about apoQlar's Series A round, please contact press@apoQlar.com.

Contact:  
Andreas Fessler
press@apoQlar.com
+1 954-675-4373

Photo - https://mma.prnewswire.com/media/1959036/apoQlar_3D_holograms.jpg
Logo - https://mma.prnewswire.com/media/1959037/apoQlar_Logo.jpg

 

(PRNewsfoto/apoQlar GmbH)

Cision View original content to obtain multimedia:https://www.prnewswire.com/news-releases/medical-metaverse-company-apoqlar-receives-fda-510k-clearance-for-its-mixed-reality-surgical-planning-platform-vsi-holomedicine-301690781.html

SOURCE apoQlar GmbH

Sun, 04 Dec 2022 23:11:00 -0600 en text/html https://markets.businessinsider.com/news/stocks/medical-metaverse-company-apoqlar-receives-fda-510-k-clearance-for-its-mixed-reality-surgical-planning-platform-vsi-holomedicine-1031952833
Killexams : Medical Styrenic Block Copolymers Market to hit $1.2 Bn by 2032, Says Global Market Insights inc.

Global Market Insights Inc.

Medical Styrenic Block Copolymers (SBC) Industry is expected to register 7% CAGR between 2023 and 2032 propelled by rising demand for oxygen mask, respiratory devices, and other medical equipment.

Selbyville, Delaware, Dec. 08, 2022 (GLOBE NEWSWIRE) --

As per the report published by Global Market Insights Inc., the global Medical Styrenic Block Copolymers Market was estimated at USD 620 mn in 2022 and is expected to surpass a valuation of $1.2 bn by 2032, progressing at a CAGR of 7% from 2023 to 2032. The report provides a detailed analysis of top winning strategies, drivers & opportunities, competitive scenario, wavering market trends, market size, statistics & estimations, and major investment pockets.

Based on the analysis, the increased emphasis on minimizing the use of PVC-based materials in medical devices and equipment will augment the demand for styrenic block copolymers across the medical sector.

PVC is widely integrated in a range of medical devices, such as gloves, nasal cannulas, catheters, enteral feeding devices, IV & blood bags, breathing circuits, oxygen masks, surgical gowns, blood bags, medical tubing, etc., due to its high durability, strength, flexibility, and ability to operate under high temperatures and harsh environments. The material is known for its superior biocompatibility, ease of processing, recyclability, resilience, and affordability.

Request for a demo of this research report @ https://www.gminsights.com/request-sample/detail/5102

However, the escalating efforts toward evaluating more biologically and environmentally friendly polymers have resulted in the emergence of several high-performance alternatives such as Styrene-ethylene butylene-styrene (SEBS) copolymer rubbers, SEBS/polypropylene blends, etc. The ongoing replacement of low-durometer, plasticized PVC in medical devices where biocompatibility holds utmost significance will positively influence the medical styrenic block copolymer through 2032.

Styrene-Butadiene-Styrene to gain traction due to exceptional durability

Styrene-Butadiene-Styrene (SBS) segment is expected to amass more than USD 460 million by 2032, depicting a more than 6% CAGR throughout the projection period. Styrene-Butadiene-Styrene exhibit similar properties to that of rubber at room temperature and thus are primarily used in applications where high durability is critical. Styrene-Butadiene-Styrene (SBS) is also extensively utilized in a range of medical devices, pharmaceutical packaging, medical bags, and tubes, driven by its easy availability, superior durability, and low-cost attributes, creating favorable growth prospects for the medical styrenic block copolymer market.

Key reasons for Medical Styrenic Block Copolymers Market growth:

  1. Rising demand for oxygen mask, respiratory devices and other medical equipment

  2. Shifting trends in minimizing PVC to reduce health issues

Increasing minimally invasive surgeries to propel product demand in tubing applications

Speaking of the application landscape, medical styrenic block copolymer industry from tubing application is primed to showcase above 6.5% CAGR from 2023 to 2032 and reach over USD 150 million by 2032. Medical tubing made of SBC depicts exceptional mechanical, thermal, and chemical properties and better clarity than PVC. These offer low drug absorption and are used in a variety of peristaltic pumps, drug delivery systems, and feeding tubes. Besides, their increasing usage in highly critical minimally invasive procedures, such as urological retrieval devices, cardiovascular catheters, stent delivery systems, etc.

Flourishing economic outlook to streamline industry growth across Asia Pacific

Asia Pacific medical styrenic block copolymers market is speculated to garner over USD 200 million by 2032. The regional growth can be credited to the robust economic landscape and a significant rise in disposable incomes, resulting in increased healthcare expenditure. Governments across numerous regional economies, including China, the Philippines, India, and Indonesia, have been emphasizing offering low-cost healthcare services, accelerating the demand for medical devices and equipment.

Request for customization of this research report @ https://www.gminsights.com/roc/5102

Footprint expansion to stimulate the competitive outlook

Major companies operating in the medical styrenic block copolymers market include Kraton Corporation, TSRC Corporation, China Petroleum & Chemical Corporation, LG Chem, Dynasol Group, Asahi Kasei Corporation, Kumho Petrochemical, LCY Chemical Corp, INEOS Styrolution Group GmbH, JSR Corporation, RTP Company, Zeon Corporation, En Chuan Chemical Industries Co., Ltd., and Trinseo SA.

Partial chapters of report table of contents (TOC):

Chapter 5   Medical Styrenic Block Copolymers (SBC) Market, By Product

5.1    Key product trends

5.2    Styrene-butadiene-styrene (SBS)

5.3    Styrene isoprene butadiene (SIBS)

5.4    Styrene ethylene butylene styrene (SEBS)

5.5    Others

Chapter 6   By Application

6.1    Key application trends

6.2    Tubing

6.3    Medical bags

6.4    Equipment’s

6.5    Packaging & diagnostics products

6.6    Wound care

6.7    Others

Browse Our Reports Store - GMIPulse @  https://www.gminsights.com/gmipulse

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

CONTACT: Contact Us: Aashit Tiwari Corporate Sales, USA Global Market Insights Inc. Toll Free: +1-888-689-0688 USA: +1-302-846-7766 Europe: +44-742-759-8484 APAC: +65-3129-7718 Email: sales@gminsights.com
Wed, 07 Dec 2022 23:10:00 -0600 en-US text/html https://www.yahoo.com/now/medical-styrenic-block-copolymers-market-131000091.html
Killexams : Palo Alto Networks Announces Medical IoT Security to Protect Connected Devices Critical to Patient Care

SANTA CLARA, Calif., Dec. 5, 2022 /PRNewswire/ — As healthcare providers use digital devices such as diagnostic and monitoring systems, ambulance equipment, and surgical robots to Boost patient care, the security of those devices is as important as their primary function. Today, Palo Alto Networks (NASDAQ: PANW) announced Medical IoT Security — the most comprehensive Zero Trust security solution for medical devices — enabling healthcare organizations to deploy and manage new connected technologies quickly and securely. Zero Trust is a strategic approach to cybersecurity that secures an organization by eliminating implicit trust by continuously verifying every user and device.

"The proliferation of connected medical devices in the healthcare industry brings a wealth of benefits, but these devices are often not well secured. For example, according to Unit 42, an alarming 75% of smart infusion pumps examined on the networks of hospitals and healthcare organizations had known security gaps," said Anand Oswal, senior vice president of products, network security at Palo Alto Networks. "This makes security devices an attractive target for cyberattackers, potentially exposing patient data and ultimately putting patients at risk."

While a Zero Trust approach is critical to help protect medical devices against today's innovative cyberthreats, it can be hard to implement in practice. Through automated device discovery, contextual segmentation, least privilege policy recommendations and one-click enforcement of policies, Palo Alto Networks Medical IoT Security delivers a Zero Trust approach in a seamless, simplified manner. Medical IoT Security also provides best-in-class threat protection through seamless integration with Palo Alto Networks cloud-delivered security services, such as Advanced Threat Prevention and Advanced URL Filtering.

The new Palo Alto Networks Medical IoT Security uses machine learning (ML) to enable healthcare organizations to:

  • Create device rules with automated security responses: Easily create rules that monitor devices for behavioral anomalies and automatically trigger appropriate responses. For example, if a medical device that typically only sends small amounts of data unexpectedly begins to use a lot of bandwidth, the device can be cut off from the internet and security teams can be alerted.
  • Automate Zero Trust policy recommendations and enforcement: Enforce recommended least-privileged access policies for medical devices with one click using Palo Alto Networks Next-Generation Firewalls or supported network enforcement technologies. This eliminates error-prone and time-consuming manual policy creation and scales easily across a set of devices with the same profile.
  • Understand device vulnerabilities and risk posture: Access each medical device's Software Bill of Materials (SBOM) and map them to Common Vulnerability Exposures (CVEs). This mapping helps identify the software libraries used on medical devices and any associated vulnerabilities. Get immediate insights into the risk posture of each device, including end-of-life status, recall notification, default password alert and unauthorized external website communication.
  • Improve compliance: Easily understand medical device vulnerabilities, patch status and security settings, and then get recommendations to bring devices into compliance with rules and guidelines, such as the Health Insurance Portability Accountability Act (HIPAA), General Data Protection Regulation (GDPR), and similar laws and regulations.
  • Verify network segmentation: Visualize the entire map of connected devices and ensure each device is placed in its designated network segment. Proper network segmentation can ensure a device only communicates with authorized systems.
  • Simplify operations: Two distinct dashboards allow IT and biomedical engineering teams to each see the information critical to their roles. Integration with existing healthcare information management systems, like AIMS and Epic Systems, helps automate workflows.

Healthcare organizations are using Palo Alto Networks products to secure the devices that deliver cutting-edge care to millions of patients all over the world.

"Establishing and maintaining acute situational awareness of the Internet of Medical Things (IoMT) environment is paramount to establishing an effective enterprise cybersecurity program. The ability to accurately detect, identify and respond to cyber threats is critical to ensuring minimal operational impact to clinical operations during a cyber event," said Tony Lakin, CISO, Moffitt Cancer Center. "Palo Alto Networks IoT capability seamlessly integrates with our continuous monitoring processes and threat-hunting operations. The platform consistently provides my teams with actionable information to allow them to proactively manage the threat surface of our medical device portfolio."

"With thousands of devices to manage, healthcare environments are extremely complex and require intelligent security solutions capable of doing more. Palo Alto Networks understands this requirement and is leveraging machine learning (ML) for Medical IoT security. Adding intelligence will enable providers to Boost operational efficiency, which will enhance patient and practitioner experience and alleviate the burden of an ongoing IT skills shortage," said Bob Laliberte, principal analyst, ESG.

"Healthcare providers continue to be high-value targets for attackers. This reality, combined with the diversity of medical IoT devices and their inherent vulnerabilities, points to a real need for device security that is purpose-built for healthcare use cases. The ability to defend against threats targeting critical care devices while maintaining operational availability and strengthening the alignment of device governance responsibilities between IT and Biomed engineering teams is quickly becoming a necessity for the protection of patient data and lives," said Ed Lee, research director, IoT and Intelligent Edge Security, IDC.

More Information

  • Learn more about Medical IoT Security here.
  • Read the Medical IoT Security announcement blog here.
  • Register to attend the Palo Alto Networks Ignite Conference on Dec. 12th - 15th, 2022, here.
  • Follow Palo Alto Networks on Twitter, LinkedIn, Facebook and Instagram.

Availability

Medical IoT Security will be available in January 2023.

About Palo Alto Networks

Palo Alto Networks is the world's cybersecurity leader. We innovate to outpace cyber threats, so organizations can embrace technology with confidence. We provide next-gen cybersecurity to thousands of customers globally, across all sectors. Our best-in-class cybersecurity platforms and services are backed by industry-leading threat intelligence and strengthened by state-of-the-art automation. Whether deploying our products to enable the Zero Trust Enterprise, responding to a security incident, or partnering to deliver better security outcomes through a world-class partner ecosystem, we're committed to helping ensure each day is safer than the one before. It's what makes us the cybersecurity partner of choice.

At Palo Alto Networks, we're committed to bringing together the very best people in service of our mission, so we're also proud to be the cybersecurity workplace of choice, recognized among Newsweek's Most Loved Workplaces (2021), Comparably Best Companies for Diversity (2021), and HRC Best Places for LGBTQ Equality (2022). For more information, visit www.paloaltonetworks.com.

Palo Alto Networks and the Palo Alto Networks logo are registered trademarks of Palo Alto Networks, Inc. in the United States and in jurisdictions throughout the world. All other trademarks, trade names, or service marks used or mentioned herein belong to their respective owners. Any unreleased services or features (and any services or features not generally available to customers) referenced in this or other press releases or public statements are not currently available (or are not yet generally available to customers) and may not be delivered when expected or at all. Customers who purchase Palo Alto Networks applications should make their purchase decisions based on services and features currently generally available.

SOURCE: Palo Alto Networks Inc.

Tue, 06 Dec 2022 13:57:00 -0600 en text/html https://www.darkreading.com/iot/palo-alto-networks-announces-medical-iot-security-to-protect-connected-devices-critical-to-patient-care
Killexams : Canary Medical Announces Introduction of Groundbreaking Orthopedic Analytic Platform

Canary Medical

  • Canary Quantiles™ Recovery Curves Compare Observed Gait Performance versus Population Gait Performance During a Patient’s Recovery from Total Knee Replacement Surgery

  • Quantiles™ Recovery Curves Utilize Data Derived from Persona IQ® to Help Healthcare Professionals with Early, At-Home Identification of Patients Who Could Benefit from Additional Care

VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Canary Medical, a medical data company focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem, today announced the introduction of its first orthopedic analytic module, Canary Quantiles™ Recovery Curves. Recovery curves utilize movement data measured by Canary Medical’s proprietary implantable canturio™te tibial extension sensor technology integrated with Zimmer Biomet’s Persona IQ® - The Smart Knee®.

Persona IQ® with canturio™te tibial extension sensor technology collects various activity measures and gait parameters for at least 10 years. By pooling multiple parameters across the Persona IQ® patient population, recovery curves provide frequent, objective aggregate population data of each patient’s activity levels and knee kinematics and ranks each patient’s knee performance versus their peers based on age group, gender and time since surgery. Clinicians can now access and use this daily functional information to determine whether to augment their in-office patient examinations and/or to update their care plans in the year following surgery. Recovery curves are the world’s first and only monitoring tool available to reproducibly characterize an individual patient’s total knee replacement recovery versus objective aggregate population data obtained from identical implantable sensors.

“Using recovery curves, I’m seeing my patients more actively engaged in their surgical recovery. With this objective data, they can see and understand their own recovery trajectory as compared to other patients. If they are falling behind, we discuss ways they can potentially Boost their recovery,” said Orthopedic Surgeon Dr. John M. Dundon, Morristown Medical Center in New Jersey. “In the future, I will be able to determine which patients are high risk for complications and poor outcomes many weeks faster than standard care. That information will allow me the opportunity to prevent surgical complications and proactively address patient recovery.”

“Today Canary Medical and Zimmer Biomet take the next step in our shared vision of changing the future of orthopedic post-operative care. Canary Quantiles Recovery Curves are another exciting example of our commitment to providing meaningful data and analysis to surgeons and their patients,” said Bill Hunter, M.D., Founding Member and Chief Executive Officer of Canary Medical. “Improvements in implanted sensors, power and transmission technologies enable more precise measurement and meaningful continuous monitoring to better understand and support patient post-operative care. We will soon expand the use of our implantable Canturio™ technology to other joints and implants, making Persona IQ® the first of many Zimmer Biomet products that will benefit from the data our sensors provide.”

Liane Teplitsky, President, Global Robotics and Technology & Data Solutions, Zimmer Biomet, added, “We continue to be excited about utilizing objective patient data to support and personalize care pre-, intra- and post-operatively with Persona IQ. We are working together with Canary to introduce recovery curves to customers in order to better understand how this novel information is being used and displayed prior to full integration with Zimmer Biomet’s mymobility® with Apple Watch platform, the primary user interface for Persona IQ data.”

“Knee replacement surgery is considered a highly successful procedure. And yet, researchers have noted that many patients are not satisfied with the results of surgery, and a significant subset develop complications that sometimes require further surgical intervention,” said Fred Cushner, M.D., Chief Surgical Officer, Canary Medical and Associate Professor, Hospital for Special Surgery. “High quality functional information obtained between office visits could help detect problems earlier and mitigate the severity of these complex cases. The data in recovery curves provides a wealth of real-world data never before available.”

As an implanted technology, data is collected passively with Persona IQ® via the canturiote tibial extension sensor technology every day*, from the same anatomic location, without charging or replacement. Automatic, at-home data collection and transmission places no additional compliance burdens on patients or clinicians and ensures data is regularly captured by canturio™te at an unprecedented success rate.

Canary Quantiles Recovery Curves are now available to all surgeons implanting Persona IQ® from the dashboard in their Canary Medical account and will enhance the information displayed on their mymobility dashboard. Access to Canary Quantiles is being provided free for a limited time, as the features of the platform continue to expand. Future planned releases of Canary Quantiles will continue to streamline office workflow, allowing HCPs to receive alerts for patients out of defined recovery parameters. Ultimately, Canary plans for the information available in Canary Quantiles to be used for remote patient monitoring, resulting in earlier identification of potential complications and/or adjustment of recovery plans, and to fulfill the attestation requirements for remote patient monitoring CPT code billing.

About Canary Medical
Canary Medical is a medical data company focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem. In 2021, Canary Medical introduced canturio™te, the world’s first “smart knee” tibial extension, which is implanted in the body where it monitors patient activity and joint performance, and transmits data to the cloud, autonomously, requiring almost no patient compliance or physician involvement. The Company was conceived and created with the vision that healthcare transformation requires reliable and cost-effective healthcare data and that the effective monitoring and analysis of that data will produce better outcomes for patients at lower costs. Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

For more information contact us at admin@canarymedical.com or visit www.canarymedical.com. Follow Canary Medical on Twitter at @CanaryMedical.

* Data is collected every day for the first year and intermittently thereafter

Investor Contact
David Dean
Canary Medical
Chief Business Development Officer
ddean@canarymedical.com     

Media Contacts
Patrick Bursey
LifeSci Communications
pbursey@lifescicomms.com
o: 646-970-4688

The Canary Quantiles™ Recovery Curves software provides health care professionals (HCPs) with additional aggregate population data when managing a patient's total knee arthroplasty (TKA) post-surgical care. HCPs can filter or select options for additional views based on patient demographics (e.g. age), to analyze trends and outcomes. The Canary Quantiles Recovery Curves software allows HCPs to view aggregate patient population data to analyze patient recovery progress and direction of outcome.

The Canary Quantiles™ Recovery Curves software does not control the function or parameters of the Canturio™ Tibial Extension (CTE) with Canary Health Implanted Reporting Processor (CHIRP™) System and is not intended for active patient monitoring.

The Canturio™ Tibial Extension Tibial Extension (CTE) with Canary Health Implanted Reporting Processor (CHIRP™) System is intended to provide objective kinematic data from the implanted medical device during a patient’s total knee arthroplasty (TKA) post-surgical care. The kinematic data are an adjunct to other physiological parameter measurement tools applied or utilized by the physician during the course of patient monitoring and treatment post-surgery.

The device is indicated for use in patients undergoing a cemented TKA procedure that are normally indicated for at least a 58mm sized tibial stem extension.

The objective kinematic data generated by the CTE with CHIRP™ System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

The CTE with CHIRP™ System is compatible with Zimmer Biomet Persona® The Personalized Knee® System.

WARNING: The kinematic data obtained from this device have not been demonstrated to have clinical benefit. It is not intended to be utilized for clinical decision-making, and no data have been evaluated by FDA regarding clinical benefits.


Legal Disclaimers
 
The information contained in this presentation, including the accompanying oral commentary, is provided solely for the purpose of acquainting you, as its recipient, with Canary Medical and its subsidiaries (the “Company”, “we”, “us” or “our”) and its executive personnel. 

This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of the Company, nor will we make any offer, solicitation or sale of such securities in any state, province or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.   

All trademarks are the exclusive property of their respective owners.

Wed, 07 Dec 2022 23:00:00 -0600 en-US text/html https://finance.yahoo.com/news/canary-medical-announces-introduction-groundbreaking-130000755.html
MSNCB exam dump and training guide direct download
Training Exams List